Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | President - Diag & Spatial Bi | August 17, 2026 | August 19, 2026 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,702 |
Reported balance
After 2026-08-17 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-08-17 · Grant · Acquired 8,702 · Balance 8,702 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F15: 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,140 |
Reported balance
After 2026-08-17 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-08-17 · Grant · Acquired 14,140 · Balance 14,140 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F16: 14,140 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 794 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 794 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 794 restricted stock units vest on 5/1/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,200 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 1,200 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 600 restricted stock units vest on each of 6/2/2027 and 6/2/2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,869 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 1,869 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 1,869 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,353 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 4,353 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13: 2,177 restricted stock units vest on 8/15/2027, and 2,176 restricted stock units vest on 8/15/2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 735 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 735 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F14: 245 restricted stock units vest on each of 3/2/2027, 3/2/2028 and 3/2/2029. |
| Common StockSEC Table I · non-derivative | Direct | 10,237 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,237 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.13 · Expires 2028-04-01 | Direct | 3,856 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,856 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 19,032 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 19,032 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 24,560 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 24,560 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 12,649 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 12,649 F2: Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.46 · Expires 2031-05-01 | Direct | 7,327 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7,327 F3: Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 17,133 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 17,133 F4: Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.61 · Expires 2035-06-02 | Direct | 5,434 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 5,434 F5: Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 19,151 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 19,151 F6: Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.82 · Expires 2036-03-02 | Direct | 1,911 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 1,911 F7: Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,387 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 2,387 F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vested.
F2: Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
F3: Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
F4: Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
F5: Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
F6: Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
F7: Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
F8: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: 794 restricted stock units vest on 5/1/2027.
F11: 600 restricted stock units vest on each of 6/2/2027 and 6/2/2028.
F12: 1,869 restricted stock units vest on 8/15/2027.
F13: 2,177 restricted stock units vest on 8/15/2027, and 2,176 restricted stock units vest on 8/15/2028.
F14: 245 restricted stock units vest on each of 3/2/2027, 3/2/2028 and 3/2/2029.
F15: 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029.
F16: 14,140 restricted stock units vest on 8/17/2029.
OmniAb, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,333 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Exercise / conversion · Acquired 20,000 · Balance 33,333 F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,667 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Exercise / conversion · Disposed 20,000 · Balance 26,667 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,667 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 20,000 · Balance 46,667 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-06-17 | Direct | 40,000 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 20:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 14,140 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000129 · form4.xml · derivative · entry 18 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,140 Underlying: Common Stock · 14,140 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F16 · derivative.exercise_date: 14,140 restricted stock units vest on 8/17/2029. F16 · derivative.expiration_date: 14,140 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 8,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000129 · form4.xml · derivative · entry 17 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,702 Underlying: Common Stock · 8,702 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F15 · derivative.exercise_date: 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029. F15 · derivative.expiration_date: 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000114 · form4.xml · derivative · entry 7 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,353 Underlying: Common Stock · 2,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. F6 · derivative.expiration_date: 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,868 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000114 · form4.xml · derivative · entry 6 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,869 Underlying: Common Stock · 1,868 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027. F5 · derivative.expiration_date: 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,379 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000114 · form4.xml · derivative · entry 5 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: 1,379 restricted stock units vest on 8/15/2026. F4 · derivative.expiration_date: 1,379 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,947 | $72.40 | $140,962.80 |
DisclosureSEC source: 0000914190-26-000114 · form4.xml · nonDerivative · entry 2 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,237 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,423 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000114 · form4.xml · nonDerivative · entry 1 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0002065241-26-000005 · wk-form4_1781814718.xml · derivative · entry 4 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-17 F4 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002065241-26-000005 · wk-form4_1781814718.xml · derivative · entry 3 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F3 · derivative.expiration_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002065241-26-000005 · wk-form4_1781814718.xml · derivative · entry 2 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F1 · derivative.expiration_date: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:32 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002065241-26-000005 · wk-form4_1781814718.xml · nonDerivative · entry 1 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000096 · form4.xml · derivative · entry 4 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028. F3 · derivative.expiration_date: 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 216 | $49.77 | $10,750.32 |
DisclosureSEC source: 0000914190-26-000096 · form4.xml · nonDerivative · entry 2 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,761 Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-26-000096 · form4.xml · nonDerivative · entry 1 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F17 · balance_after: Due to a mathematical error on the Form 4 filed May 5, 2026, the number of shares beneficially owned is being increased by 40 shares and this filing represents the correct number of shares beneficially owned by the Reporting Person. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 794 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000083 · form4.xml · derivative · entry 3 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794 Underlying: Common Stock · 794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 794 restricted stock units vest on 5/1/2026 and 5/1/2027. F2 · derivative.expiration_date: 794 restricted stock units vest on 5/1/2026 and 5/1/2027. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 311 | $55.02 | $17,111.22 |
DisclosureSEC source: 0000914190-26-000083 · form4.xml · nonDerivative · entry 2 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,337 Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-26-000083 · form4.xml · nonDerivative · entry 1 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 20:05 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0002065241-26-000003 · wk-form4_1776801914.xml · derivative · entry 2 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU which occurs in three substantially equal annual installments, beginning April 21, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents the vesting of an RSU which occurs in three substantially equal annual installments, beginning April 21, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 20:05 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002065241-26-000003 · wk-form4_1776801914.xml · nonDerivative · entry 1 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU which occurs in three substantially equal annual installments, beginning April 21, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 1,911 | $0.00 Strike: $57.82 | $0.00 |
DisclosureSEC source: 0000914190-26-000036 · form4.xml · derivative · entry 17 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,911 Underlying: Common Stock · 1,911 shares Expires 2036-03-02 F16 · derivative.exercise_date: Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 735 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000036 · form4.xml · derivative · entry 16 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735 Underlying: Common Stock · 735 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F15 · derivative.exercise_date: 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029. F15 · derivative.expiration_date: 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 2,387 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000036 · form4.xml · derivative · entry 15 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,387 Underlying: Common Stock · 2,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F14 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F14 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:13 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0002065241-25-000007 · wk-form4_1750277584.xml · derivative · entry 2 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-17 F3 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:13 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002065241-25-000007 · wk-form4_1750277584.xml · derivative · entry 1 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2 · derivative.expiration_date: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 23:52 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0002065241-25-000005 · wk-form4_1745279560.xml · derivative · entry 2 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-04-21 F3 · derivative.exercise_date: The Stock Option grant vests and becomes exercisable in three substantially equal annual installments beginning on April 21, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 23:52 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002065241-25-000005 · wk-form4_1745279560.xml · derivative · entry 1 Crouse Steven C. · CIK 0002065241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU grant vests in three substantially equal annual installments beginning on April 21, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The RSU grant vests in three substantially equal annual installments beginning on April 21, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.